Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Average Price Target of $4.00

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $4.00.

A number of research firms have issued reports on TNYA. Weiss Ratings lowered Tenaya Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 10th. Wall Street Zen upgraded Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, September 6th.

View Our Latest Stock Analysis on TNYA

Hedge Funds Weigh In On Tenaya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Tenaya Therapeutics during the 2nd quarter valued at $2,963,000. Empery Asset Management LP acquired a new stake in Tenaya Therapeutics in the 2nd quarter worth $2,855,228. GSA Capital Partners LLP acquired a new stake in Tenaya Therapeutics in the 2nd quarter worth $1,973,000. Renaissance Technologies LLC grew its position in Tenaya Therapeutics by 100.6% in the 1st quarter. Renaissance Technologies LLC now owns 3,713,761 shares of the company’s stock worth $2,571,000 after purchasing an additional 1,862,894 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Tenaya Therapeutics in the 2nd quarter worth $1,150,000. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Price Performance

Tenaya Therapeutics stock opened at $0.29 on Thursday. The company has a market capitalization of $65.32 million, a price-to-earnings ratio of -0.58 and a beta of 2.88. Tenaya Therapeutics has a one year low of $0.28 and a one year high of $1.46. The company’s fifty day moving average price is $0.47 and its two-hundred day moving average price is $0.68.

Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, sell-side analysts anticipate that Tenaya Therapeutics will post -0.36 earnings per share for the current year.

Tenaya Therapeutics Company Profile

(Get Free Report)

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for heart disease. Based in South San Francisco, California, the company uses genetic medicine and other therapeutic approaches to target the underlying causes of cardiac conditions. Its investigational programs include TN-201, a gene therapy candidate for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.

Recommended Stories

Analyst Recommendations for Tenaya Therapeutics (NASDAQ:TNYA)

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.